OnCusp Therapeutics is transforming a growing portfolio of cutting-edge molecules into innovative treatments to deliver hope to cancer patients worldwide.
Our translational expertise and global industry network make us the optimal partner to transform cutting-edge research assets into clinically proven therapeutics.
OnCusp Therapeutics Announces Encouraging Initial Phase 1a Results from Ongoing First-in-Human Study Evaluating its CDH6-Directed Antibody-Drug Conjugate, CUSP06, in Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors at the 2025 ASCO Annual Meeting
OnCusp Therapeutics Receives FDA Fast Track Designation for CUSP06 for the Treatment of Platinum-Resistant Ovarian Cancer
